44 related articles for article (PubMed ID: 19320241)
1. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy.
Chadwick EG; Yogev R; Alvero CG; Hughes MD; Hazra R; Pinto JA; Robbins BL; Heckman BE; Palumbo PE; Capparelli EV;
AIDS; 2011 Mar; 25(5):643-9. PubMed ID: 21297419
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.
Cressey TR; Jourdain G; Rawangban B; Varadisai S; Kongpanichkul R; Sabsanong P; Yuthavisuthi P; Chirayus S; Ngo-Giang-Huong N; Voramongkol N; Pattarakulwanich S; Lallemant M;
AIDS; 2010 Sep; 24(14):2193-200. PubMed ID: 20625263
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial to assess safety, tolerability, and antepartum viral load with increased lopinavir/ritonavir dosage in pregnancy.
Bonafe SM; Costa DA; Vaz MJ; Senise JF; Pott-Junior H; Machado RH; Castelo A
AIDS Patient Care STDS; 2013 Nov; 27(11):589-95. PubMed ID: 24138537
[TBL] [Abstract][Full Text] [Related]
4. Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.
Santos JR; Muñoz-Moreno JA; Moltó J; Prats A; Curran A; Domingo P; Llibre JM; McClernon DR; Bravo I; Canet J; Watson V; Back D; Clotet B
PLoS One; 2013; 8(7):e70201. PubMed ID: 23922957
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.
Sutherland KA; Ghosn J; Gregson J; Mbisa JL; Chaix ML; Cohen Codar I; Delfraissy JF; Delaugerre C; Gupta RK
J Antimicrob Chemother; 2015 Jan; 70(1):243-8. PubMed ID: 25228587
[TBL] [Abstract][Full Text] [Related]
6. Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy.
Reina E; San Miguel R; Larrea N; Garcia P; Napal V
Int J Clin Pharm; 2012 Dec; 34(6):911-6. PubMed ID: 23007692
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
Ghosn J; Delaugerre C; Flandre P; Galimand J; Cohen-Codar I; Raffi F; Delfraissy JF; Rouzioux C; Chaix ML
PLoS One; 2011; 6(9):e24798. PubMed ID: 21949754
[TBL] [Abstract][Full Text] [Related]
8. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.
Delaugerre C; Flandre P; Chaix ML; Ghosn J; Raffi F; Dellamonica P; Jaeger H; Shürmann D; Cohen-Codar I; Van PN; Norton M; Taburet AM; Delfraissy JF; Rouzioux C;
Antimicrob Agents Chemother; 2009 Jul; 53(7):2934-9. PubMed ID: 19451297
[TBL] [Abstract][Full Text] [Related]
9. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
Bierman WF; van Agtmael MA; Nijhuis M; Danner SA; Boucher CA
AIDS; 2009 Jan; 23(3):279-91. PubMed ID: 19114854
[TBL] [Abstract][Full Text] [Related]
10. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.
Tan D; Walmsley S
Expert Rev Anti Infect Ther; 2007 Feb; 5(1):13-28. PubMed ID: 17266450
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.
Flandre P; Delaugerre C; Ghosn J; Chaix ML; Horban A; Girard PM; Gladysz A; Cohen-Codar I; Van PN; Taburet AM; Rouzioux C; Delfraissy JF;
Antivir Ther; 2009; 14(1):93-7. PubMed ID: 19320241
[TBL] [Abstract][Full Text] [Related]
12. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
[TBL] [Abstract][Full Text] [Related]
13. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
14. Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results.
Voigt E; Wasmuth JC; Vogel M; Mauss S; Schmutz G; Kaiser R; Rockstroh JK
Infection; 2004 Apr; 32(2):82-8. PubMed ID: 15057572
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
